Ginkgo Bioworks Holdings, Inc.

Ginkgo Bioworks Holdings, Inc. (NYSE: DNA) reached public markets through its de-SPAC merger with Soaring Eagle Acquisition Corp, a blank-check company sponsored by Eagle Equity Partners and led by serial SPAC operators Harry Sloan, Jeff Sagansky, and Eli Baker. Soaring Eagle completed its initial public offering in February 2021, filing its final prospectus on Form 424B4. The business combination with Ginkgo Bioworks — a synthetic biology company that engineers custom microorganisms for pharmaceutical, industrial, food, and agricultural customers — closed in September 2021, with the combined entity listing on the New York Stock Exchange under the ticker DNA. The transaction established Ginkgo as one of the largest SPAC-backed biotechnology deals of that cycle. Sign up on SpacDesk for the full filing history, shareholder data, and deal analytics on DNA and hundreds of other SPAC transactions.